Does BEVACIZUMAB Cause Hepatocellular carcinoma? 532 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 532 reports of Hepatocellular carcinoma have been filed in association with BEVACIZUMAB (JOBEVNE). This represents 0.7% of all adverse event reports for BEVACIZUMAB.
532
Reports of Hepatocellular carcinoma with BEVACIZUMAB
0.7%
of all BEVACIZUMAB reports
285
Deaths
72
Hospitalizations
How Dangerous Is Hepatocellular carcinoma From BEVACIZUMAB?
Of the 532 reports, 285 (53.6%) resulted in death, 72 (13.5%) required hospitalization, and 19 (3.6%) were considered life-threatening.
Is Hepatocellular carcinoma Listed in the Official Label?
Yes, Hepatocellular carcinoma is listed as a known adverse reaction in the official FDA drug label for BEVACIZUMAB.
What Other Side Effects Does BEVACIZUMAB Cause?
Off label use (12,094)
Death (8,493)
Diarrhoea (4,911)
Disease progression (4,653)
Fatigue (4,572)
Nausea (4,357)
Hypertension (4,309)
Anaemia (3,221)
Vomiting (3,193)
Neutropenia (2,875)
What Other Drugs Cause Hepatocellular carcinoma?
SORAFENIB (1,665)
RIBAVIRIN (1,046)
SOFOSBUVIR (877)
LEDIPASVIR\SOFOSBUVIR (640)
REGORAFENIB (470)
DACLATASVIR (419)
ATEZOLIZUMAB (342)
CABOZANTINIB S-MALATE (219)
TACROLIMUS (183)
SOFOSBUVIR\VELPATASVIR (161)
Which BEVACIZUMAB Alternatives Have Lower Hepatocellular carcinoma Risk?
BEVACIZUMAB vs BEVACIZUMAB-AWWB
BEVACIZUMAB vs BEVACIZUMAB-BVZR
BEVACIZUMAB vs BEVACIZUMAB-MALY
BEVACIZUMAB vs BEXAROTENE
BEVACIZUMAB vs BEYAZ